CytoDyn Inc (CYDY) is a leading biotechnology business based in the US. It opened the day at $1.56 after a previous close of $1.60. During the day the price has varied from a low of $1.55 to a high of $1.60. The latest price was $1.58 (25 minute delay). CytoDyn is listed on the OTCQB and employs 19 staff. All prices are listed in US Dollars.
How to buy shares in CytoDyn
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CYDY – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
CytoDyn stock price (OTCQB: CYDY)Use our graph to track the performance of CYDY stocks over time.
CytoDyn shares at a glance
|52-week range||$1.35 - $7.40|
|50-day moving average||$1.75|
|200-day moving average||$3.25|
|Wall St. target price||$4.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.19|
Buy CytoDyn shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy CytoDyn stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
CytoDyn price performance over time
|1 week (2021-07-19)||N/A|
|1 month (2021-06-30)||-7.06%|
|3 months (2021-04-30)||-49.68%|
|6 months (2021-01-26)||N/A|
|1 year (2020-07-26)||N/A|
|2 years (2019-07-26)||N/A|
|3 years (2018-07-26)||N/A|
|5 years (2016-07-26)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-80.94%|
|Return on equity TTM||0%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
CytoDyn share dividends
We're not expecting CytoDyn to pay a dividend over the next 12 months.
CytoDyn share price volatility
Over the last 12 months, CytoDyn's shares have ranged in value from as little as $1.35 up to $7.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.5593. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). It has completed a Phase 3 pivotal trial with leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. The company is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. In addition, the company targets leronlimab treatment as a therapy for patients who experience respiratory complications as a result of contracting COVID-19, as well as Leronlimab for the prevention of graft-versus-host disease in patient.
Stocks similar to CytoDyn
CytoDyn in the news
OTC Markets Hits Major Milestones in Mid-Year Along With Big Volume and Gaining Securities
Large shareholder group calls for a board overhaul at pharma company CytoDyn
CytoDyn to hold a pharmaceutical update conference call
Frequently asked questionsWhat percentage of CytoDyn is owned by insiders or institutions?
Currently 13.065% of CytoDyn shares are held by insiders and 0.134% by institutions. How many people work for CytoDyn?
Latest data suggests 19 work at CytoDyn. When does the fiscal year end for CytoDyn?
CytoDyn's fiscal year ends in May. Where is CytoDyn based?
CytoDyn's address is: 1111 Main Street, Vancouver, WA, United States, 98660 What is CytoDyn's ISIN number?
CytoDyn's international securities identification number is: US23283M1018 What is CytoDyn's CUSIP number?
CytoDyn's Committee on Uniform Securities Identification Procedures number is: 23283M101
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert